Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) will report first quarter 2026 financial results before market open on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a corporate update.

Investors can join the live webcast via the company’s Events & Presentations page or dial in at 800-715-9871 (domestic) or +1 646-307-1963 (international) using Conference ID 9970701. A replay will be archived for 90 days.

Argus Apr 30 session

+4.80% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – PVLA

On Apr 30, the day this news came out, PVLA closed 4.80% above the previous close.

Data tracked by StockTitan Argus for the Apr 30 session.

Key Figures

Q1 2026 results date: May 7, 2026 Conference call time: 8:30 a.m. ET Conference ID: 9970701 +3 more

Q1 2026 results date

May 7, 2026

Scheduled financial results release before market open

Conference call time

8:30 a.m. ET

Start time for Q1 2026 results and corporate update call

Conference ID

9970701

ID required to join the Q1 2026 conference call

Domestic dial-in

800-715-9871

U.S. phone access number for the call

International dial-in

+1 646-307-1963

International phone access number for the call

Replay duration

90 days

Length of time webcast replay will remain archived

Previous Conferences,earnings Reports

5 past events · Latest: Mar 24

Same Type 5 events

1. Mar 24

   Results call notice

   24h Move

   -0.7%

   Scheduled full year 2025 results call and corporate update for Mar 31, 2026.

2. Nov 04

   Results call notice

   24h Move

   -2.3%

   Announced Q3 2025 results release and update call on Nov 11, 2025.

3. Aug 07

   Results call notice

   24h Move

   -0.1%

   Set Q2 2025 financial results and corporate update call for Aug 14, 2025.

4. May 08

   Results call notice

   24h Move

   +4.4%

   Scheduled Q1 2025 results and corporate update call for May 15, 2025.

5. Mar 18

   Results call notice

   24h Move

   +1.3%

   Planned full year 2024 financial results call and update on Mar 31, 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical-stage, biopharmaceutical, U.S. Food and Drug Administration (FDA), vascular malformations, +1 more

5 terms

clinical-stage medical

"a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

biopharmaceutical medical

"a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

U.S. Food and Drug Administration (FDA) regulatory

"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

vascular malformations medical

"rare skin diseases and vascular malformations for which there are no U.S. Food"

Abnormalities in the network of blood vessels present from birth that cause vessels to form oddly sized, shaped or connected channels rather than a normal, orderly pipeline; think of plumbing pipes that developed wrong connections and leak or bulge. They matter to investors because they create a defined patient group and clinical need that can drive demand for diagnostic tools, treatments, regulatory approvals and reimbursement decisions, affecting company revenues and risk profiles.

webcast technical

"To access the live webcast, including slides, please click here or visit"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

To access the live webcast, including slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To join the conference call by phone, dial 800-715-9871 (domestic) or +1 646-307-1963 (international) and provide Conference ID 9970701. Participants are encouraged to dial in approximately 15 minutes prior to the start of the call.

A replay of the webcast will be available approximately two hours after the call concludes and will be archived for 90 days in the “Events & Presentations” section of the Company’s website at www.palvellatx.com.

About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Palvella Therapeutics (PVLA) release Q1 2026 results and hold the conference call?

Palvella will release Q1 2026 results before market open on Thursday, May 7, 2026. According to the company, management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and give a corporate update.

How can investors access the Palvella (PVLA) May 7, 2026 webcast and slides?

Investors can access the live webcast and slides on the company’s Events & Presentations web page. According to the company, the webcast includes slides and a replay will be available about two hours after the call and archived for 90 days.

What dial-in numbers and conference ID are for the Palvella (PVLA) May 7, 2026 call?

Dial 800-715-9871 (domestic) or +1 646-307-1963 (international) and use Conference ID 9970701. According to the company, participants are encouraged to dial in approximately 15 minutes before the 8:30 a.m. ET start time to ensure timely access.

Will a replay of the Palvella (PVLA) Q1 2026 call be available and for how long?

Yes, a replay will be available approximately two hours after the call concludes. According to the company, the replay will be archived on the Events & Presentations page and remain accessible for 90 days following the call.